Mesothelioma

Shares were up 7% after Study Results Demonstrating Potential of Alfacell's ONCONASE.

BellwetherReport.com is a leading online research firm for international investors looking to get an edge over their portfolio.

Investors seeking the most up to date information on Alfacell Corp are invited to sign up for a free complimentary subscription to www.bellwetherreport.com.

No credit card needed!

Alfacell Corporation announced that in vivo study results demonstrating the potential of ONCONASE (ranpirnase) for the treatment of non-small cell lung cancer (NSCLC) were recently published in Anticancer Research (2007; 27: 299- 308).

Based on the work of Intae Lee, Ph.D., at the University of Pennsylvania, a paper entitled "Antitumor Efficacy of the Cytotoxic RNase, Ranpirnase, on A549 Human Lung Cancer Xenografts of Nude Mice" shows that: * ONCONASE significantly inhibited tumor growth of A549 NSCLC cells both in vitro and in vivo; apoptosis was significantly induced by ONCONASE in a dose-dependent manner * Multiple small doses of ONCONASE were more effective than one large single dose of ONCONASE for the inhibition of tumor growth in animal studies * ONCONASE in combination with cisplatin significantly reduced tumor growth of A549 cells; in large tumors, including those unsuccessfully t...

Read more...